Rena Conti

@contirena1

health economics & policy; pharmaceutical supply, demand & prices; professor at BU Questrom, 🇨🇮

United States
Vrijeme pridruživanja: veljača 2016.

Tweetovi

Blokirali ste korisnika/cu @contirena1

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @contirena1

  1. prije 10 sati
    Poništi
  2. 4. velj

    Yes I’m looking for data on this too! Please send my way

    Poništi
  3. 3. velj
    Poništi
  4. 1. velj
    Poništi
  5. 31. sij
    Poništi
  6. 31. sij
    Poništi
  7. 30. sij

    Yes in theory list price increases could result in stable net prices

    Poništi
  8. 29. sij

    Our prescription supply chain is opaque and vulnerable. phrna views manufacturing location, drug identity and volume as trade secrets. It’s time for increased transparency. See our work on this:

    Poništi
  9. 29. sij

    Yes is correct. Branded competition within therapeutic category results in lower net prices, related to discounts and rebates for most drugs.

    Poništi
  10. 29. sij
    Poništi
  11. 28. sij
    Poništi
  12. 28. sij
    Poništi
  13. 28. sij
    Poništi
  14. 28. sij
    Poništi
  15. 28. sij
    Poništi
  16. 25. sij
    Poništi
  17. 24. sij

    Wait! I’m confused. Are you saying there are real offsets associated with these therapies??? Can’t wait to see the empirical data supporting this claim! Please send my way

    Poništi
  18. 23. sij
    Poništi
  19. 22. sij
    Poništi
  20. 22. sij

    An easy fix already exists - Trump administration already allowed high deductible health plans to exempt some rescue meds/devices from deductible payments; could do the same in commercial plans. Thx

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·